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Background: The incremental value of 18FDG PET/CT in patients with breast cancer (BC) compared to conventional
imaging (CI) in clinical practice is unclear. The aim of this study was to evaluate the management impact and
prognostic value of 18 F-FDG PET/CT in this setting.
Methods: Sixty-three patients who were referred to our institution for suspicion of BC relapse were retrospectively
enrolled. All patients had been evaluated with CI and underwent PET/CT. At a median follow-up of 61 months,
serial clinical, imaging and pathologic results were obtained to validate diagnostic findings. Overall Survival (OS)
was estimated using Kaplan Meier methods and analyzed using the Cox proportional hazards regression models.
Results: Forty-two patients had a confirmed relapse with 37 (88%) positive on CI and 40 (95%) positive on PET/CT.
When compared with CI, PET/CT had a higher negative predictive value (86% versus 54%) and positive predictive
value (95% versus 70%). The management impact of PET/CT was high (change of treatment modality or intent) in
30 patients (48%) and medium (change in radiation treatment volume or dose fractionation) in 6 patients (9%).
Thirty-nine patients (62%) died during follow-up. The PET/CT result was a highly significant predictor of OS
(Hazard Ratio [95% Confidence Interval] =4.7 [2.0-10.9] for PET positive versus PET negative for a systemic recurrence;
p = 0.0003). In a Cox multivariate analysis including other prognosis factors, PET/CT findings predicted survival
(p = 0.005). In contrast, restaging by CI was not significant predictor of survival.
Conclusion: Our study support the value of 18 F-FDG PET/CT in providing incremental information that influence
patient management and refine prognostic stratification in the setting of suspected recurrent breast cancer.
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Breast cancer (BC) is the most commonly diagnosed
cancer in women, and is the leading cause of death by
cancer for women in the western world. Depending on
the initial extent of the disease, approximately 30% of
patients diagnosed with BC are at risk of developing
loco-regional recurrence or secondary tumor dissemin-
ation to distant organs [1]. Moreover, the survival of pa-
tients who develop an isolated loco-regional recurrence* Correspondence: ACochet@dijon.fnclcc.fr
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unless otherwise stated.differs from patients who have distant relapse. As a con-
sequence, determination of both the locations and extent
of the recurrent disease is essential to guide therapeutic
decisions and estimate prognosis.
Traditionally, routine evaluation of suspected recurrent
BC involves physical examination and a multi-modality
Conventional Imaging (CI) approach which may include
mammography, CT, MRI, and bone scintigraphy. How-
ever, this CI approach is often time-intensive and potential
false-negative findings may delay appropriate therapy.
Positron Emission Tomography/Computed Tomography
(PET/CT) with 18 F-Fluorodeoxyglucose (18 F-FDG) is also
often used in this indication, given that 18 F-FDG has
affinity for both primary and secondary breast tumors,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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thors have suggested that 18 F-FDG PET and PET/CT are
more sensitive than CI for detection of recurrent BC [5-15]
and can have a significant impact on the therapeutic man-
agement [5,7-9,12,16]. However, information concerning
the utility of 18 F-FDG PET/CT for long-term prognostic
stratification, when compared with CI, is limited.
Thus, the objectives of our study were to: [1] assess
the incremental diagnostic performance and the impact
on therapeutic management of 18 F-FDG PET/CT in a
group of patients with a history of BC who had already
been restaged by CI for identification of suspected dis-
ease relapse; [2] compare the long-term prognostic
stratification of CI alone and 18 F-FDG PET/CT.
Methods
Patients
A retrospective analysis was performed on consecutive
patients with a history of BC and suspicion of recurrence
who were referred for 18 F-FDG PET/CT at our institu-
tion from January 2002 to September 2008. BC was not
a funded indication of 18 F-FDG PET/CT during this
period in Australia; therefore, clinicians usually referred
patients with high suspicion of recurrence for PET/CT.
The inclusion criteria of the study were as follows: (a)
a history of confirmed histologic diagnosis of primary
BC treated as per local protocol; (b) CI performed no
longer than 4 months prior to PET/CT and where the
CI included at least a CT scan of the area of interest; (c)
availability of follow-up data for a minimum of 6 months
following PET/CT; (d) unequivocal determination of
clinical status at the time of the last clinical follow-up.
Sixty-three patients (62 women and one man; mean
age = 57 years; range = 29-86 years) were included. The
median time interval from initial diagnosis to 18 F-FDG
PET/CT was 39 months (range 5-431 months). The me-
dian time interval between CT and PET/CT was 25 days
(first-third quartile: 1-52 days). Indications for PET/CT
were: equivocal or suspicious CI findings (n = 28); clinical
suspicion of recurrence (n = 21); restaging after comple-
tion of therapy (n = 5); routine surveillance (n = 5); and
increasing levels of tumor markers (n = 4). All patients
provided permission to review medical records at the time
of PET/CT imaging according to our institution’s investi-
gational review board guidelines for informed consent
(protocol number 09/78).
PET/CT acquisition and processing
Whole-body PET was acquired sequentially using a dedi-
cated PET/CT system (Discovery LS PET/ 4-slice helical
CT or Discovery STE/ 8-slice helical CT, General Elec-
tric Medical Systems, Milwaukee, WI) combining a mul-
tidetector CT scanner with a dedicated, full-ring PET
scanner with bismuth germanate crystals. Patients wereinstructed to fast except for glucose-free oral hydration
for at least 6 hours before injection of 300-400 MBq
of 18 F-FDG. PET was performed 60 min following 18 F-FDG
injection. Blood glucose levels were measured before the
injection of the tracer to ensure levels below 10 mmol/l.
Transmission data used for attenuation correction were
obtained from a low-dose non diagnostic CT acquisition
(140 kVp and 40-120 mA), without contrast enhancement.
Attenuation corrected PET images were reconstructed
with an iterative reconstruction (ordered-subset expect-
ation maximization algorithm). Orthogonal CT, PET, and
fused PET/CT images were displayed simultaneously on a
GE Xeleris Workstation. The PET data were also dis-
played in a rotating maximum-intensity projection.
An experienced nuclear medicine physician generated
a clinical report after reviewing PET images, low-dose
CT images, fused PET/CT images, previous imaging re-
sults and clinical information. Standard uptake values
were not routinely measured. Once issued, the PET/CT
report was not reinterpreted in the light of subsequent
clinical information.
Image interpretation and classification
A total of 188 clinical, imaging and pathological procedures
were performed (3 ± 1.4 per patients), including chest CT
(n = 59), abdominopelvic CT (n = 44), whole-body bone scan
(n = 30), clinical examination (n = 17), pathology (n = 9), ab-
dominal ultrasound (US) (n = 7), MRI (n = 7), mammogram
or breast US (n = 6), chest radiography (n = 5), other (n = 5).
Written clinical reports of conventional images and
PET/CT were reviewed and classified as (a) negative if im-
aging tests were negative for disease; (b) equivocal, when
abnormal findings were present on any imaging test but
were not interpreted as suspicious for malignancy; (c)
positive, if any result was clearly described as suspicious or
consistent with malignancy. Negative and equivocal find-
ings were combined as negative for the analysis.
In cases where recurrence was reported on CI or PET/
CT, the location of relapse was also determined, and
classified as loco-regional (ipsilateral breast, ipsilateral
axillary, internal mammary or supraclavicular node sta-
tion) or systemic (contralateral node station or distant
metastasis). The final diagnosis of disease recurrence and
location of disease was confirmed by histologic examin-
ation in 13 patients (21%). For the remaining patients, evi-
dence of progression within 6 months of clinical and/or
imaging follow-up was considered to indicate a site of dis-
ease relapse, whereas no evidence of progression after at
least 6 months of follow-up was considered to confirm ab-
sence of active disease at that site.
Assessment of impact
Referring physicians were asked to record a pre-PET/CT
management plan before PET/CT results on our routine
Table 1 Patient characteristics at the time of initial
diagnosis
Characteristics Number of patients (%)








































HER-2 = Human Epidermal Growth Factor Receptor-2.
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ment plan and treatment intent were determined from the
medical record or by contacting the referring clinician.
The impact of PET/CT on management was consid-
ered “high” when the treatment intent or modality was
changed (e.g. from palliative to curative treatment or
from surgery to radiotherapy) [17]. The impact was con-
sidered as “medium” when the method of treatment de-
livery was changed (e.g. radiation treatment volume and/
or dose fractionation) [17]. When the PET/CT results
did not indicate a need for change, the impact was con-
sidered to be “low”. PET/CT was considered to have had
“no impact” when the management chosen conflicted
with post-PET/CT disease extent on the basis of a syn-
thesis of all available information.
Follow-up
After PET/CT, progress updates were obtained from the
medical record, family physician, or treating oncologist.
When relevant, details of the date and cause of death
were obtained. The disease status at the time of death
was recorded.
Statistical analysis
Estimates of OS at 2 and 5 years were computed using the
Kaplan Meier method, a log-rank test was used to analyze
the effect of CI and PET/CT results on OS. Two Cox re-
gression analyses were performed to assess the impact of
PET/CT and CI on OS controlling for clinical variables
and using a backward elimination process. Triple negative
status of the primary tumor was not included in the multi-
variate model because this information was available for
only 38 patients. For percentages such as PPV, NPV, sensi-
tivity and specificity, a Blyth-Still-Casella 95% confidence
interval (CI) was calculated. Diagnosis performance results
were compared using McNemar tests, Fisher exact tests
and a likelihood ratio, which summarizes how many times
more likely patients with the disease are to have that par-
ticular result than patients without the disease. According
to the fact that patients were selected on the basis of CI,
many patients with unequivocal systemic relapse on CI
would likely not have been referred for PET/CT. Given
the likely pre-test selection bias, positive and negative
predictive values were considered as more relevant com-
parators of diagnostic performance when compared with
sensitivity and specificity.
Results
Patient characteristics at the time of initial diagnosis are
summarized in Table 1.
Diagnostic performance
Relapse involving at least one site was confirmed in 42
of the 63 patients (67%). CI was positive for disease in
Table 2 Comparison of extent of suspected relapse as assessed before and after PET/CT
Pre-PET/CT
extent of relapse





disease by PET/CTNegative LR only Systemic Total
Negative 8 1 3 12 - 66 33
LR only 1 6 1 8 12.5 75 12.5
Systemic 12 1 30 43 30 70 -
Total 21 8 34 63 22 70 8
LR = Loco-Regional; PET/CT = Positron Emission Tomography/Computerized Tomography.
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whereas PET/CT was positive for disease in 40, corre-
sponding to a patient sensitivity of 95%.
Table 2 shows comparison of extent of suspected re-
lapse as assessed before and after PET/CT. Downstaging
by PET/CT was confirmed to be correct in 12/14 pa-
tients (one patient had a suspicious bony lesion on bone
scan that was non 18 F-FDG-avid, but confirmed to be
malignant; one patient showed suspicious mediastinal
lymph nodes on CT that were non 18 F-FDG-avid but
confirmed to be metastasis of breast cancer by path-
ology), while upstaging with PET/CT was confirmed in
5/5 patients.
On final diagnosis, 20 patients (32%) had a loco-regional
recurrence and 36 (57%) had a systemic recurrence
(14 patients had both loco-regional and systemic recur-
rence). CI was truly positive for loco-regional recurrence
in 8/20 patients (40%) and systemic recurrence in 30/36
patients (83%). PET/CT was truly positive for loco-
regional recurrence in 20/20 patients (100%) and systemic
disease in 32/36 patients (89%). Among the 20 patients
experiencing loco-regional recurrence, only 3 had local re-
lapse only, for whom both PET/CT and CI were positive.
PET/CT detected regional relapse non-detected by CI in
12 patients (3 in axillary nodes only, 9 in extra-axillary
nodes). PET/CT had significantly higher positive predict-
ive values when compared with CI for determination ofTable 3 Diagnostic accuracy of conventional imaging (CI) and




Conventional Imaging 7/13 (54%) 29–82
PET/CT 19/22 (86%) 70–98
Locoregional recurrence: 63
Conventional Imaging 41/53 (77%) 65–88
PET/CT 42/42 (100%) 93–100 <
Systemic recurrence: 63
Conventional imaging 14/19 (74%) 50–89
PET/CT 26/29 (90%) 74–97
CI = Confidence Interval; PET/CT = Positron Emission Tomography/Computerized To
*likelihood ratio = sensitivity/ (1-specificity).loco-regional, systemic and global recurrence, and higher
negative predictive value for loco-regional and global re-
currence (Table 3). 18 F-FDG PET/CT found incidental
malignancies in 2 patients (one patient had a primary
esophageal cancer and one patient had a gastrointestinal
stromal tumor).Impact on management
The PET/CT results had a high impact on management
in 30 patients (48%) of whom the treatment intent was
modified in 24 patients (including from invasive diagno-
sis to observation for 11 patients, according to negative
PE/CT results despite suspicious CI findings). For the 6
remaining patients, the treatment intent was not modi-
fied after PET/CT (palliative for 5 patients, curative for
1 patient), but the modalities of therapy were changed.
PET/CT had a medium impact on management in
6/63 patients (9%). Management changes in these pa-
tients primarily included changes in radiation treatment
volume as a result of more extensive disease detected by
PET/CT. All these patients had a palliative treatment in-
tent, which was not modified by PET/CT.
PET/CT had a low impact (i.e. did not change the
planned management) in 27/63 patients (43%) for whom
the relapse extent was concordant with that found on
CI (19 patients) or the documentation of a differentPET/CT in detecting relapse of disease in all patients,
ystemic recurrence
Positive predictive value Likelihood
p 95% CI p Ratio*
35/50 (70%) 59–84 1.3
0.05 39/41 (95%) 84–99 0.003 9.8
8/10 (80%) 44–96 8.6
0.001 20/21 (95%) 78–100 0.24 43
31/44 (70%) 56–82 1.8
0.24 33/34 (97%) 85–100 0.002 24.8


















0 1 2 3 4 5 6 7 8 9
years following PET
Number at risk
63 47 41 32 15 12 8 6 1 0
Figure 1 Estimated overall survival (+/- 95% confidence
interval) for all 63 patients.
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ment (2 patients), or both PET/CT and CI findings were
negative (6 patients). In no case was the PET/CT result
apparently ignored.Prediction of survival by CI and PET/CT
Survival data were analyzed with a close-out date of
September, 4th 2010. The median follow-up time was
5.1 years (range 0.8-8.6 years). All 63 patients entered
into the study had a known status at the close-out
date. All patients with negative PET/CT findings were
followed for a minimum of 2 years after the scan (except

















0 1 2 3 4 5 6 7 8 9
years following PET/CT
Number at risk
12 11 10 8 3 3 2 2 1 0CI -
8 7 6 5 3 2 1 0 0 0CI + (LR)





Figure 2 Overall survival by staging technique. (A) Kaplan-Meier estima
imaging) status. (B) Kaplan-Meier estimate of OS stratified by post-PET/CT s
Syst = systemic recurrence.of complications of an esophageal primary tumor discov-
ered on PET/CT).
Thirty-eight patients (60%) were deceased with a
median survival of 3.4 years (95% CI 2.5 to 5.0 years)
(Figure 1). The estimated 2-year OS was 66.4% (95% CI
53.2% to 76.6%) and the estimated 5-year OS was 37.3%
(95% CI 24.3% to 50.3%).
On univariate analysis, PET/CT status (negative, posi-
tive LR or positive systemic) was strongly associated
with survival (log-rank test: p = 0.0003 for the entire
model; p = 0.0001 for comparison of negative results and
positive for systemic disease; p > 0.05 for other single
comparisons) (Figure 2). Patients with systemic disease
according to PET/CT had a 4.7-fold in the risk of death
when compared with patients with negative PET/CT
findings, while patients with only loco-regional recur-
rence had a 2-fold increase in the risk of death (Table 4).
In contrast, CI status (negative, positive LR or positive
systemic) did not significantly predict OS (log-rank test:
p = 0.07 for the entire model; p > 0.05 for all single com-
parisons) (Figure 2). Moreover, patients with positive
CI findings but negative PET/CT findings had similar es-
timated survival to patients in whom both tests were
negative, whereas patients with negative CI findings but
positive PET/CT results had comparable estimated sur-
vival to patients in whom both procedures were positive
for recurrence (Figure 3).
Initial stage of the disease at the time of diagnosis,
histological type of cancer and triple negative status
(hormone receptor and HER-2 negativity) were also pre-
dictors of survival on the univariate analysis (Table 4).
Time between initial diagnosis and the restaging PET/
CT, initial histological grade, estrogen receptor status,
progesterone receptor status and overexpression of


















0 1 2 3 4 5 6 7 8 9
years following PET/CT
Number at risk
21 20 20 15 8 8 6 5 1 0ET-
9 7 6 5 2 1 0 0 0 0ET+ (LR)
33 20 15 12 5 3 2 1 0 0ET+ (Syst.)
te of overall survival (OS) stratified by pre-PET/CT (Conventional
tatus. CI = Conventional Imaging; LR = loco-regional recurrence only;
Table 4 Univariate predictors of overall survival
Cox regression
Relative hazard rate
No. pts HR 95% CI Logrank test
All patients 63
Time between diagnosis and PET/CT 0.94
0 to 3 years 33 1.00 (Reference)
4 to 9 years 16 1.13 (0.54 – 2.37)
10+ years 14 1.07 (0.47 – 2.46)
Histological type 0.018
Invasive ductal carcinoma 42 1.00 (Reference)
Invasive lobular carcinoma 11 2.83 (1.34 – 6.02)
Mixed, Mucinous and other 7 1.66 (0.66 – 4.40)
T 0.0004
T1 29 1.00 (Reference)
T2 17 2.94 (1.33 – 6.50)
T3/T4 13 4.70 (1.99 – 11.05)
N 0.27
N 31 1.00 (Reference)
N+ 29 1.43 (0.75 – 2.75)
Stage at diagnosis 0.009
Stage I 19 1.00 (Reference)
Stage II 19 3.05 (1.17 – 7.90)
Stage III/IV 21 3.68 (1.51 – 9.00)
Histological grade 0.92
1 and 2 28 1.00 (Reference)
3 25 1.04 (0.52 – 2.05)
ER status 0.067
Positive 34 1.00 (Reference)
Negative 20 1.87 (0.95 – 3.68)
PR status 0.29
Positive 25 1.00 (Reference)
Negative 28 1.45 (0.73 – 2.88)
HER-2 status* 0.85
Positive 9 1.00 (Reference)
Negative 29 1.09 (0.44 – 2.73)
Triple negative status* 0.0003
At least one Positive 27 1.00 (Reference)
Triple Negative 9 5.28 (1.99 – 14.00)
CI findings 0.07
Negative 12 1.00 (Reference)
Positive - loco regional 8 1.54 (0.38 – 6.16)
Positive - systemic 43 2.89 (1.02 – 8.18)
PET/CT findings 0.0003
Negative 21 1.00 (Reference)
Positive - loco regional 9 2.02 (0.59 – 6.98)
Positive - systemic 33 4.71 (2.03 – 10.93)
*The information is available for only 38 patients.
CI = Confidence Interval; ER = Estrogen Receptor; HER-2 = Human Epidermal Growth Factor Receptor-2; HR = Hazard Ratio; PET/CT = Positron Emission
Tomography/Computerized Tomography; PR = Progesterone Receptor. Significant p values in bold.


















0 1 2 3 4 5 6 7 8 9
years following PET/CT
Number at risk
8 8 8 6 3 3 2 2 1 0Both - 
38 24 19 15 7 4 2 1 0 0Both +
13 12 12 9 5 5 4 3 0 0CI + /PET -
4 3 2 2 0 0 0 0 0 0CI - /PET +
Both - 
Both +
CI + /PET -
CI - /PET +
p=0.04
Figure 3 Kaplan-Meier estimate of overall survival (OS)
stratified by combination of Conventional imaging (CI) and
PET/CT results.
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ate analysis, positive PET/CT findings (for loco-regional
and/or systemic recurrence) remained an independent
predictor of OS when adjusting for age, histological sub-
type and initial stage (model 1, Table 5). In contrast,
positive CI findings did not independently predict OS
(model 2, Table 5).
Discussion
For patients with possible recurrent breast cancer (BC),
early detection and adequate localization of recurrent
disease are essential for guiding optimal therapy and
prognostication. Patients with isolated loco-regional re-
currence are able to benefit from curative salvage ther-
apy, whereas palliative treatment is generally indicated
for patients with distant relapse.Table 5 Multivariate predictors of overall survival
No of observed
Model 1 36/58
Age (per 10 years)
Invasive ductal carcinoma vs. other type
Initial stage II, III, IV vs. I
PET/CT positive vs negative
Model 2 36/58
Age (per 10 years)
Invasive ductal carcinoma vs. other
Initial stage II, III, IV vs. I
Conventional Imaging positive vs. negative
CI = Confidence Interval; HR = Hazard Ratio; PET/CT = Positron Emission TomographSeveral studies have shown the relevance of 18 F-FDG
PET/CT in detecting distant metastasis in patients with
clinical suspicion of recurrence [6,8,12,13,18-20], and in
patients with documented loco-regional recurrence [5].
Our study confirmed that 18 F-FDG PET/CT is an accur-
ate technique for the appropriate detection of relapse,
when compared with CI alone. Of particular economic
and clinical importance was the observation that 12 pa-
tients (19%) in this series who were suspected to have
relapsed by conventional evaluation subsequently re-
ceived no active treatment after a negative 18 F-FDG
PET/CT evaluation and demonstrated an excellent prog-
nosis. In contrast, of the 8 patients with negative CI find-
ings, 1 patient was found to have locoregional relapse and
3 patients were found to have systemic recurrence on
18 F-FDG PET/CT. In the current study, 18 F-FDG PET/
CT had an impact on therapeutic management in 57% of
patients; in particular, the treatment intent was changed in
38% of patients. This result is consistent with other studies
which showed the important impact of 18 F-FDG PET/CT
on therapeutic management in patients with suspicion of
recurrent BC [5,8,12,18,19]. Most of these previous studies
reported that 18 F-FDG PET/CT was highly accurate for
detecting recurrent disease in patients with negative or in-
conclusive CI findings [5,18,19]. In contrast, in our study,
CI findings were consistent with relapse in the majority of
patients (51/63) but 18 F-FDG PET/CT downstaged 12 of
them, providing a better negative predictive value when
compared to CI alone (Table 3). These findings suggested
that 18 F-FDG PET/CT was not only effective for early de-
tection of relapse in patients with negative CI findings, but
also yielded a better characterization of CI findings in pa-
tients with a high suspicion of relapse.
As BC was not a funded indication of 18 F-FDG PET/
CT in Australia during the study period, referring
clinicians were likely to use PET/CT in patients for
whom there was clinical uncertainty with respect to the









y/Computerized Tomography. Significant p values in bold.
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pact of PET/CT findings on patient management, it also
showed the value of 18 F-FDG PET/CT in patients whose
disease status could not be adequately determined using
CI alone.
The more accurate prognostic information derived
from PET/CT results when compared with CI findings
underpinned the value of PET/CT in the management
of patients with recurrent BC. Both 18F-FDG PET/CT
and CT are not optimal modalities for detection of local
recurrence, when compared with mammography, ultra-
sound or MRI. However, detection of additional distant
metastases in patients with documented loco-regional
recurrence is essential in order to optimize management
and stratify prognosis. Of note was the favourable sur-
vival of patients with isolated loco-regional recurrence
according to PET/CT, when compared with patients
with systemic relapse.
In our study, CT performed with PET was not of diag-
nostic quality. However, all patients included in this study
had diagnostic CT before undergoing FDG PET/CT.
While Dirisamer et al. showed in a retrospective study
that the association of FDG PET and contrast-enhanced
(ce) CT could improve restaging of breast cancer when
compared with ceCT or FDG PET alone [6], there is no
evidence in the literature of the superiority of FDG PET/
ceCT for restaging of breast cancer when compared with
FDG PET associated to non-diagnostic, low dose CT. In
our study, the outcome data validate our approach in
that FDG PET/CT results were more often correct than
conventional imaging (including diagnostic CT) when
discordant, and stratified prognosis whereas conven-
tional imaging did not (Figure 2). If we hadn’t ignored
the conventional imaging findings (including diagnostic
CT) when discordant with FDG PET/CT, the accuracy
wouldn’t have been enhanced and the prognostic value
of FDG PET/CT incorporating a low dose, non-contrast
CT wouldn’t have been superior to that of conventional
imaging. These results have implications for the report-
ing of FDG PET combined with ceCT, which is per-
formed by some facilities as a routine procedure and
suggest that significant clinical weight should be placed
on the PET findings even when discordant with the
ceCT appearances.
One of the limitations of our study was that the CI
procedures were not standardized and were selected on
the basis of clinical findings. However, this represented
routine clinical practice and did not detract from the
results. Although comparison of a masked reading of
PET/CT with a masked reading of CI techniques might
be appropriate if PET/CT were to be suggested as a re-
placement for CI, the main purpose of this study was to
evaluate the incremental diagnostic and prognostic value
of PET/CT in routine practice. The results of thisretrospective study would, however, justify a randomized
trial in which patients with clinical risk or suspicion of
relapse would be stratified to have either CI or FDG
PET/CT as the initial restaging procedure [21]. Finally,
we did not compare PET/CT and CI findings with histo-
pathological findings in most patients. For 50 patients
(79%), the final disease status was determined clinically
and/or with follow-up imaging. Nevertheless, since most
of the patients were followed up for a long period of
time, the survival analysis would be the best validation
of diagnostic accuracy.
Conclusion
Our findings support the value of 18 F-FDG PET/CT in
providing incremental information that influence patient
management and refine prognostic stratification in the
setting of suspected recurrent breast cancer. The prog-
nostic stratification provided by this technique empha-
sizes the crucial role of 18 F-FDG PET/CT in optimizing
treatment choices in this setting. Further multicentric
studies are needed to confirm this role in particular in
patients with high suspicion of relapse.
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